TRIAL WATCH PCSK9 antibody reduces LDL cholesterol

被引：30
|
作者：
Crunkhorn, Sarah
机构：
来源：
NATURE REVIEWS DRUG DISCOVERY | 2012年 / 11卷 / 01期
关键词：
D O I：
10.1038/nrd3633
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：11 / 11
页数：1
相关论文
共 50 条
  • [41] Inhibition of PCSK9: A powerful weapon for achieving ideal LDL cholesterol levels
    Steinberg, Daniel
    Witztum, Joseph L.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (24) : 9546 - 9547
  • [42] INFLUENCE OF PHYSIOLOGICAL CHANGES IN ENDOGENOUS ESTROGEN ON CIRCULATING PCSK9 AND LDL CHOLESTEROL
    Ghosh, M.
    Galman, C.
    Rudling, M. A. T. S.
    Angelin, B. O.
    ATHEROSCLEROSIS, 2015, 241 (01) : E16 - E16
  • [43] Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol
    Schwartz, Gregory G.
    Szarek, Michael
    Bittner, Vera A.
    Diaz, Rafael
    Goodman, Shaun G.
    Jukema, J. Wouter
    Landmesser, Ulf
    Lopez-Jaramillo, Patricio
    Manvelian, Garen
    Pordy, Robert
    Scemama, Michel
    Sinnaeve, Peter R.
    White, Harvey D.
    Steg, Ph Gabriel
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 78 (05) : 421 - 433
  • [44] PCSK9 Inhibitors: Novel Therapeutic Strategies for Lowering LDL-Cholesterol
    Wang, Yan
    Liu, Zhao-Peng
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2019, 19 (02) : 165 - 176
  • [45] Influence of physiological changes in endogenous estrogen on circulating PCSK9 and LDL cholesterol
    Ghosh, Moumita
    Gaelman, Cecilia
    Rudling, Mats
    Angelin, Bo
    JOURNAL OF LIPID RESEARCH, 2015, 56 (02) : 463 - 469
  • [46] A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo
    Ni, Yan G.
    Di Marco, Stefania
    Condra, Jon H.
    Peterson, Laurence B.
    Wang, Weirong
    Wang, Fubao
    Pandit, Shilpa
    Hammond, Holly A.
    Rosa, Ray
    Cummings, Richard T.
    Wood, Dana D.
    Liu, Xiaomei
    Bottomley, Matthew J.
    Shen, Xun
    Cubbon, Rose M.
    Wang, Sheng-ping
    Johns, Douglas G.
    Volpari, Cinzia
    Hamuro, Lora
    Chin, Jayne
    Huang, Lingyi
    Zhao, Jing Zhang
    Vitelli, Salvatore
    Haytko, Peter
    Wisniewski, Douglas
    Mitnaul, Lyndon J.
    Sparrow, Carl P.
    Hubbard, Brian
    Carfi, Andrea
    Sitlani, Ayesha
    JOURNAL OF LIPID RESEARCH, 2011, 52 (01) : 78 - 86
  • [47] New CETP inhibitor K-312 reduces PCSK9 expression: a potential effect on LDL cholesterol metabolism
    Miyosawa, Katsutoshi
    Watanabe, Yuichiro
    Murakami, Kentaro
    Murakami, Takeshi
    Shibata, Haruki
    Iwashita, Masaya
    Yamazaki, Hiroyuki
    Yamazaki, Koichi
    Ohgiya, Tadaaki
    Shibuya, Kimiyuki
    Mizuno, Ken
    Tanabe, Sohei
    Singh, Sasha A.
    Aikawa, Masanori
    AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2015, 309 (02): : E177 - E190
  • [48] Cholesterol reduction with PCSK9 inhibitors
    Lambooij A.
    Huisarts en wetenschap, 2018, 61 (9) : 18 - 20
  • [49] PCSK9: a convertase that coordinates LDL catabolism
    Horton, Jay D.
    Cohen, Jonathan C.
    Hobbs, Helen H.
    JOURNAL OF LIPID RESEARCH, 2009, 50 : S172 - S177
  • [50] STRUCTURE AND TRAFFICKING OF PCSK9 IN LDL BINDING
    Matteucci, Sara
    Pravata, Valentina
    Esposito, Francesco Maria
    Arnaboldi, Lorenzo
    Gianazza, Erica
    Grigore, Liliana
    Banfi, Cristina
    Catapano, Alberico
    ATHEROSCLEROSIS, 2024, 395
12345